Eli Lilly pays $1B upfront to buy gene editing partner Verve Therapeutics

Eli Lilly is acquiring gene editing partner Verve Therapeutics for $1.3 billion, including contingent value rights, to bring Verve's cardiovascular gene editing programs in-house. The deal, which follows prior investments and collaborations between the two companies, is driven by promising early-stage data from VERVE-102, a gene editing therapy targeting PCSK9 to lower LDL cholesterol, with Lilly aiming to shift cardiovascular disease treatment towards a 'one-and-done' approach. This acquisition is part of Lilly's broader strategy of acquiring promising pipelines, as demonstrated by recent deals including Scorpion Therapeutics and SiteOne Therapeutics.

Analysis

Eli Lilly's definitive agreement to acquire Verve Therapeutics for up to $1.3 billion, including $10.50 per share in cash and an additional $3 per share in contingent value rights (CVR), marks a strategic deepening of its investment in gene editing for cardiovascular diseases. This price represents a substantial premium over Verve's $6.27 closing share price prior to the announcement. The acquisition brings Verve's promising pipeline, particularly VERVE-102, entirely under Lilly's control, following earlier financial commitments including a $60 million upfront payment to Verve in 2023 and a $250 million payment to Beam Therapeutics in 2023 for opt-in rights to Verve's programs. The move is significantly influenced by positive early-stage clinical data for VERVE-102, which demonstrated a reduction in LDL cholesterol and PCSK9 levels without the liver enzyme elevations that led to the discontinuation of a previous candidate, thereby validating Verve's refined lipid nanoparticle delivery technology. This transaction is consistent with Lilly's aggressive M&A strategy observed in 2025, highlighted by other notable acquisitions such as Scorpion Therapeutics' PI3Kα pipeline (up to $2.5 billion) and SiteOne Therapeutics, signaling a clear focus on acquiring innovative assets with the potential for paradigm-shifting treatments, such as Verve’s envisioned 'one-and-done' therapy for cardiovascular conditions. Lilly's group vice president, Ruth Gimeno, underscored VERVE-102's potential as a first-in-class in vivo gene editing therapy for broad patient populations, aiming to address significant unmet needs.

Key Decisions for Investors

• For Eli Lilly (LLY) investors, this acquisition strengthens its cardiovascular pipeline with innovative gene editing technology and aligns with its strategy of pursuing high-growth areas, though successful integration of Verve and continued positive clinical development of VERVE-102 will be crucial for realizing long-term value.
• Verve Therapeutics (VERV) shareholders are presented with a significant premium through the $10.50 per share cash offer, plus potential further upside from the $3 CVR tied to VERVE-102's Phase 3 trial initiation, making continued holding of shares until deal completion a logical step to maximize returns.
• Investors in Beam Therapeutics (BEAM) should recognize that Lilly’s outright acquisition of Verve effectively concludes Beam's prior $250 million opt-in rights deal concerning these specific Verve programs, and they should monitor for any disclosures regarding the final impact or any residual relationship concerning the intellectual property involved.